Mehrdad Mobasher, MD, MPH, Chief Medical Officer at Corvus Pharmaceuticals, discusses the latest research with CPI-818 for treating autoimmune lymphoproliferative syndrome (ALPS).

ALPS is a rare pediatric genetic disorder that results in lymphadenopathy, splenomegaly, cytopenias, and autoimmunity. The disease is due to a mutation in the Fas gene that results in immune dysregulation.

CPI-818 is a selective ITK (interleukin-2-inducible T-cell kinase) inhibitor. At ASH 2020, data was presented showing the drug to be effective in ALPS preclinical studies.

For more information about this and other hematologic conditions, visit